Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man

British Journal of Clinical Pharmacology
H H KupferschmidtS Krähenbühl

Abstract

Saquinavir is a potent HIV protease inhibitor whose effectiveness is limited in vivo by its low bioavailability. Since saquinavir is metabolized by CYP3A4, the effect of grapefruit juice, an inhibitor of CYP3A4, was investigated on its bioavailability. After an overnight fast, eight healthy volunteers were treated with either 400 ml grapefruit juice or water before intravenous (12 mg) or oral saquinavir (600 mg) was administered. Serial blood samples were obtained over the following 24 h and standardized meals were served 5 and 10 h after the administration of saquinavir. The plasma concentrations of saquinavir were determined by high-performance liquid chromatography and pharmacokinetic parameters were calculated by routine methods. The AUC was not affected by grapefruit juice after intravenous administration, but it increased significantly from 76+/-96 (water, mean (s.d.) to 114+/-70 (microg l[-1] h) (grapefruit juice) after oral saquinavir. Similarly, the oral bioavailability of saquinavir increased by a factor of 2 with grapefruit juice (from 0.7% to 1.4%). In contrast, clearance, volume of distribution and elimination half-life of saquinavir were not affected by grapefruit juice. After oral, but not after intravenous admin...Continue Reading

References

Feb 2, 1991·Lancet·D G BaileyJ M Arnold
Apr 20, 1990·Science·N A RobertsA Kröhn
Oct 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·P AshornB Moss
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·N E KohlI S Sigal
Jan 1, 1982·European Journal of Clinical Pharmacology·H I PirttiahoU Pitkänen
Jul 1, 1995·Clinical Pharmacology and Therapeutics·H H KupferschmidtS Krähenbühl
Apr 15, 1995·Lancet·V S KitchenJ N Weber
Apr 15, 1995·Lancet·G C YeeD T Lowenthal
Oct 1, 1994·British Journal of Clinical Pharmacology·K ArankoK T Olkkola
May 1, 1994·Survey of Ophthalmology·G RavalicoM Crocé
Jun 10, 1993·The New England Journal of Medicine·M S Hirsch, R T D'Aquila
Jun 1, 1993·Clinical Pharmacology and Therapeutics·D G BaileyJ D Spence
Jun 15, 1996·Annals of Internal Medicine·J M SchapiroT C Merigan
May 1, 1996·Clinical Pharmacology and Therapeutics·K E ThummelG R Wilkinson
Jul 1, 1996·Clinical Pharmacology and Therapeutics·D G BaileyJ D Spence
Sep 1, 1996·British Journal of Clinical Pharmacology·K T KivistöH K Kroemer
Jul 4, 1997·Journal of Chromatography. B, Biomedical Sciences and Applications·H R HaS Krähenbühl

❮ Previous
Next ❯

Citations

Nov 11, 2003·Critical Reviews in Oncology/hematology·Jeffrey C Delafuente
Jun 12, 2013·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Su-A KimHyo-Kyung Han
Sep 29, 2001·Advanced Drug Delivery Reviews·B AgoramM B Bolger
Jun 6, 2000·Advanced Drug Delivery Reviews·X Li, W K Chan
Dec 21, 2000·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·H Suzuki, Y Sugiyama
Jan 30, 2003·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Nathalie Le Goff-KleinGeneviève Ubeaud
Jan 16, 2003·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·M GiorgiG Soldani
Mar 24, 2004·Inflammopharmacology·Costas Ioannides
Apr 18, 2001·Journal of Clinical Pharmacology·M J SheltonR DiFrancesco
Nov 1, 2007·Nutrition Journal·Jawad Kiani, Sardar Z Imam
Nov 30, 2011·Drug Metabolism and Pharmacokinetics·Kanoko EgashiraIchiro Ieiri
Apr 30, 2002·Clinical Pharmacokinetics·Margaret M Doherty, William N Charman
Feb 27, 2003·Clinical Pharmacokinetics·Monique M R de MaatJos H Beijnen
Dec 15, 2010·Drugs·Kay SedenDavid Back
Jun 6, 2002·British Journal of Clinical Pharmacology·Meret Martin-FacklamWalter E Haefeli
Apr 18, 2002·Antimicrobial Agents and Chemotherapy·D DemarlesA M Taburet
Jan 27, 2004·Antimicrobial Agents and Chemotherapy·Hervé TroutJean-François Bergmann
Feb 5, 2000·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·T HansenA Bader
Aug 3, 2004·The Journal of Pharmacy and Pharmacology·N Le Goff-KleinG Ubeaud
Sep 3, 2004·Journal of Clinical Pharmacology·Kiman KimHartmut Derendorf
May 18, 2004·Journal of Clinical Pharmacology·Shiew-Mei Huang, Lawrence J Lesko
Apr 28, 2006·The Journal of Pharmacy and Pharmacology·Vilasinee Hirunpanich, Hitoshi Sato
Nov 15, 2006·Journal of Clinical Pharmacology·S U Mertens-TalcottV Butterweck
Nov 25, 2005·British Journal of Clinical Pharmacology·Jari J LiljaPertti J Neuvonen
Dec 12, 2012·Biopharmaceutics & Drug Disposition·Sravanthi CheetiJin Y Jin
Aug 7, 2004·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Marc LindenbergJennifer B Dressman
Feb 4, 2006·Life Sciences·Marilyn E Morris, Shuzhong Zhang
Feb 28, 2002·Best Practice & Research. Clinical Gastroenterology·C Herrlinger, U Klotz
May 1, 2008·Drug Metabolism and Pharmacokinetics·Motohiro Kato
Mar 9, 2010·Drug Metabolism and Pharmacokinetics·Aleksandra GaletinJ Brian Houston
Oct 7, 2016·Acta Pharmaceutica Sinica. B·Fang XieQing-Yu Zhang
Jul 12, 2007·Phytotherapy Research : PTR·S S LeeH F Kung

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.